Back to top
more

AMN Healthcare Services (AMN)

(Real Time Quote from BATS)

$37.90 USD

37.90
355,948

+1.00 (2.71%)

Updated Nov 4, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.

IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.

Best Value Stocks to Buy for January 27th

by Zacks Equity Research

UMC, AMN, and FNB made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 27, 2022

New Strong Buy Stocks for January 27th

by Zacks Equity Research

AMN, UMC, MRTN, FNB, and SLB have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2022.

Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates

by Zacks Equity Research

Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.

AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $96.13, moving -0.3% from the previous trading session.

Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

Here's Why You Should Add Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.

Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings

by Zacks Equity Research

With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.

SmileDirectClub (SDC) Moves up on New Strategic Actions

by Zacks Equity Research

SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID

by Zacks Equity Research

Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.

Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.

BD (BDX) Hits a New 52-Week High: What's Behind the Rally?

by Zacks Equity Research

A slew of strategic acquisitions are driving the top line for BD (BDX).

Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings

by Zacks Equity Research

With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.

Walgreens (WBA), Village MD Plan to Expand Into Arizona

by Zacks Equity Research

Walgreens (WBA) and VillageMD to improve access to overall care for patients with chronic conditions by opening eight new Village Medical at Walgreens primary care practices in the Tucson area.

OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment

by Zacks Equity Research

Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.